Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion.
about
KLF15 Is a transcriptional regulator of the human 17beta-hydroxysteroid dehydrogenase type 5 gene. A potential link between regulation of testosterone production and fat stores in womenPoly Cystic Ovarian Syndrome: An Updated OverviewFunctional genomics of PCOS: from GWAS to molecular mechanismsScientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.Phenotype and Tissue Expression as a Function of Genetic Risk in Polycystic Ovary SyndromeCLINICAL PRACTICE. Polycystic Ovary Syndrome.Epidemiological and molecular mechanisms aspects linking obesity and cancer.Hyperandrogenemia in obese peripubertal girls: correlates and potential etiological determinants.Characterization of functionally typical and atypical types of polycystic ovary syndrome.The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome.Estrogen-progestagen therapy in the management of the polycystic ovary syndrome.Abnormal glucose tolerance and insulin resistance in polycystic ovary syndrome amongst the Taiwanese population- not correlated with insulin receptor substrate-1 Gly972Arg/Ala513Pro polymorphismInsulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.Naturally occurring mutations of the luteinizing-hormone receptor: lessons learned about reproductive physiology and G protein-coupled receptors.Downregulation of both gene expression and activity of Hsp27 improved maturation of mouse oocyte in vitroMolecular mechanisms of sex determination in reptiles.The long term health consequences of polycystic ovary syndrome.Mutations of the hexose-6-phosphate dehydrogenase gene rarely cause hyperandrogenemic polycystic ovary syndrome.Premature ovarian failure in androgen receptor-deficient mice.Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study.Adrenal hyperandrogenism is induced by fetal androgen excess in a rhesus monkey model of polycystic ovary syndrome.Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity.Pathogenesis of polycystic ovary syndrome: evidence for a genetically determined disorder of ovarian androgen production.Obstructive sleep apnea and metabolic dysfunction in polycystic ovary syndromeThe role of steroids in follicular growth.Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome.Identification of a functional polymorphism of the human type 5 17beta-hydroxysteroid dehydrogenase gene associated with polycystic ovary syndrome.Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youthThe role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome.The Polycystic Ovary Morphology-Polycystic Ovary Syndrome Spectrum.Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test.Adolescent polycystic ovary syndrome due to functional ovarian hyperandrogenism persists into adulthood.Genetic and environmental aspect of polycystic ovary syndrome.Prevalence and clinical predictors of insulin resistance in reproductive-aged thai women with polycystic ovary syndrome.Han Chinese polycystic ovary syndrome risk variants in women of European ancestry: relationship to FSH levels and glucose toleranceEstrogen receptor-alpha mediates an intraovarian negative feedback loop on thecal cell steroidogenesis via modulation of Cyp17a1 (cytochrome P450, steroid 17alpha-hydroxylase/17,20 lyase) expression.Prenatal Testosterone Treatment Leads to Changes in the Morphology of KNDy Neurons, Their Inputs, and Projections to GnRH Cells in Female SheepFertility biomarkers to estimate metabolic risks in women with polycystic ovary syndrome.The pubertal timing controversy in the USA, and a review of possible causative factors for the advance in timing of onset of puberty.Polycystic Ovary Syndrome and Obstructive Sleep Apnea
P2860
Q24650529-B5D5F2E6-A9B9-4963-A0F3-2E61A0F35A88Q26752564-DF1F64FB-CE27-4F7A-873B-D26F81B5B8AFQ28083015-DACCB40E-1FAB-49BD-BDC7-72A3C4C13487Q28390200-F75EE16F-54CD-4CC0-BB44-3FBEA15728F2Q28468373-5A3579C9-9861-4759-9509-1A329072743BQ29248890-F6568EC8-758F-4878-95D9-75ABE42048B2Q30377470-5393A358-8BA8-42AB-BF67-A63B0F7A7110Q30432558-E3FFB0F8-95F6-462D-B314-BC757D05E271Q30436274-B550CC56-4F16-4D32-B2B9-2DBAB71C072FQ30440354-98A77036-B6F4-4A62-AA08-337274805D0DQ30472945-F472E696-666A-4A1B-AA03-847402089FA4Q33239296-EA6B3057-2FBB-436F-8784-5FF0C7C76418Q33569169-CD57A9A1-F9E7-4223-95CF-0760C746CD67Q33732533-D14DCE76-769C-4B00-AD49-93F01B4CE7A8Q33933900-4BDD4736-4C6F-4146-8997-74BFDBD3FA4FQ34053997-9791947E-7B27-4011-99A0-1D1597DE584EQ34105196-84254E6E-BE77-4EE0-8EB0-677316397E55Q34148090-ACF3C23C-A700-4CDE-916E-72A199686B98Q34248205-CD26411C-B186-43A0-B3EC-450F8C1F5F77Q34252237-DDA5D52C-2E71-4828-9CCA-79A28591ECBFQ34312465-B25E8516-039F-4327-87BE-517654604DDEQ34354008-61258297-2330-455E-BF06-3454DEF6DEC8Q34530596-03F7952C-5D22-449A-9351-DF8CF3B0018FQ34536081-BC0C711B-951A-4C9E-8E0D-A158A2F2026FQ34599318-7A2F7029-9822-4B85-B156-E5CBD9FD5BCFQ34758574-947E7D43-9B64-49A5-B9DE-DB42B41D7D45Q34863558-86EC4917-042E-4762-9414-AAFA48613A93Q34871227-776141B9-CEBD-4675-B8BF-C43368F2D126Q34994296-3799D23A-BA9C-4992-A60E-47499A6E5F6CQ35287911-79D99FDF-BDE5-4980-8ABE-BFA67FC3EE4EQ35389228-A720809A-8842-4F34-A065-32D3608BF0F7Q35442243-A00C585F-FB49-41C5-8C90-40FFE39FE6CAQ35685428-6880B8F7-582E-4F1A-89D2-47DB00C78904Q35687495-0011A2A7-2A64-4CBC-9BB0-170978449547Q35837595-08547B76-4C13-482C-A322-EBB99280E0A4Q35851170-923CBFCA-FB9C-4954-B60C-AF562DE77B9EQ35970866-0AB5EF07-FB93-4420-B44C-BB2500C2ADC6Q36378559-BD00BB67-6E34-46C7-B6FB-7100BCE4D985Q36525991-03EE7991-22DA-43B3-8126-5D633E6F754EQ36666354-B799BDEA-91DD-47F1-BE35-8D877ACB6B6F
P2860
Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Polycystic ovary syndrome as a ...... ulation of androgen secretion.
@en
type
label
Polycystic ovary syndrome as a ...... ulation of androgen secretion.
@en
prefLabel
Polycystic ovary syndrome as a ...... ulation of androgen secretion.
@en
P2093
P356
P1433
P1476
Polycystic ovary syndrome as a ...... ulation of androgen secretion.
@en
P2093
Ehrmann DA
Rosenfield RL
P304
P356
10.1210/ER.16.3.322
P577
1995-06-01T00:00:00Z